Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today

TheMotleyFool

0 0

Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today

After reporting disappointing interim news from its phase 3 study of SPN-810 as a treatment for aggressive impulses in ADHD patients, shares in Supernus Pharmaceuticals (NASDAQ: SUPN) tumbled 23.4% today.

Supernus Pharmaceuticals markets two commercial-stage epilepsy medicines, but a lot of investor's optimism has been tied instead to SPN-810, a drug that's being evaluated in two phase 3 trials for use in controlling aggressive impulses in ADHD patients.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com